BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 28, 2026
See today's BioWorld
Home
» Biogen Idec Getting Conforma In Buyout Worth Up To $250M
To read the full story,
subscribe
or
sign in
.
Biogen Idec Getting Conforma In Buyout Worth Up To $250M
May 4, 2006
By
Karen Carey
In an effort to augment its oncology pipeline, Biogen Idec Inc. signed a definitive merger agreement to acquire Conforma Therapeutics Corp. for $150 million at closing, plus up to $100 million in development milestone payments. (BioWorld Today)
BioWorld